Category Archives: Medicine

Yet another alternative to test breast cancer

Quest Diagnosis, a medical testing company, announced recently of developing a new genetic test to  diagnose breast cancer. The test has been named as BRC Advantage.

While reading this news, my mind took me into my childhood memories. I was 8 when my loving grandmother passed away. She died at a very early age of 50 as she was late in diagnosing her breast cancer. If she was a little more aware about the various breast cancer tests available, she might have lived longer.

Womens Health

Womens Health

The new test developed is capable of identifying BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two), genes responsible for normal growth and functioning of the breast cells. But any kinds of abnormalities (mutations) in these cells can lead to an increased risk of breast or ovarian cancer.

Earlier a company, Myriad Genetics had a patent on these two BRCA genes which gave the company an exclusive holding on testing any mutations in these genes.

But a recent US Supreme Court ruling has invalidated this patent thus making the two BRCA genes available to other companies for developing their own tests. Breast Cancer Therapies Markets

And why not? A naturally occurring gene is a nature’s product and not a mere patent. And very  soon the Supreme Court’s decision seems to be showing results with Quest Diagnosis coming with its first such test called BRC Advantage. The test is currently available in 49 US states and more than 2100 service centers. Quest Diagnosis hopes to increase the availability of these tests at high risking populations.

Reading about this new breast cancer test, questions still keep pouring in my mind that even after enough number of tests available, are we women actually aware about them?

Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis

Medical Devices Reports

http://www.aarkstore.com/reports/Renal-Dialysis-Equipment-Market-to-2017-Lower-Costs-and-Similar-Efficacy-Rates-as-Hemodialysis-to-Increase-Adoption-Rates-of-Peritoneal-Dialysis-197986.html

Artificial Kidneys Promise Freedom for Dialysis Patients and Savings for Hospitals
The Wearable Artificial Kidney (WAK) will offer patients across the world suffering from kidney failure freedom from endless hospital appointments – and hospitals the chance to save on resources – states a new report by medical industry experts GBI Research.

The new report, “Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis” shows the growing prevalence of diabetes and hypertension, alongside an increasingly large elderly population, has meant that doctors have encountered a rapid growth in the number of patients suffering from End Stage Renal Disease (ESRD), which has put pressure on burgeoning healthcare budgets. However, the lucrative market these patients represent for dialysis device manufacturers has led to the development of the WAK, the latest innovation to provide patient care on a global scale.

One in 10 adults are at risk of chronic kidney disease (CKD), totaling roughly 500 million people worldwide, and the rising diabetic population is increasing the prevalence of diabetic nephropathy, which is a leading cause of CKD and ESRD. Serious kidney damage demands medical attention, and the Wearable Artificial Kidney (WAK) is the latest treatment option, offering continuous dialysis treatment to patients with ESRD by using nanomaterials such as carbon nanotubes to imitate normal kidney function. Individuals gain a dramatically improved quality of life, as treatment requires minimal patient intervention.

The global renal dialysis equipment market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6% to $12.7 billion during 2010-2017. Dialysis accessories will continue to be the largest sub-segment, and will grow at a CAGR of 6% during the forecast period..

Advancing Molecular Diagnostics to Personalize Cancer Therapy

Advancing Molecular Diagnostics to Personalize Cancer Therapy

This report analyzes current and potential world markets for key cancer-based molecular diagnostics, including advances in the field. This report forecasts future growth to 2016. Market segments covered include: breast cancer; colon cancer; prostate cancer; non-small cell lung cancer; melanoma; and renal cancer. This report reviews the direction of research, and key issues facing the industry.

Features and benefits
* Identify key innovations in molecular diagnostics for oncology that may compete with those in development at your company.
* Understand the regulatory challenges facing the developers of molecular diagnostics for cancer.
* Understand the challenges that surround successfully commer-cializing a combined drug-diagnostic product and learn how to overcome them.
* Discover and analyze the key technology platforms being used in the development of novel molecular diagnostics.
* Discover the forecast market size for key segments of the cancer diagnostics market including: breast, colorectal, prostate, lung, and renal cancer.

Highlights
Advances in genomics, proteomics, molecular imaging, and other new technologies are leading to a molecularly based reclassification of malignancy, creating market opportunities for diagnostic companies.
Companion diagnostics – linking drugs with diagnostics – is expected to become the prevailing health care model, offering advantages for both the prescription drug and diagnostics businesses. For diagnostics companies, combining with a successful companion drug can be a powerful driver of sales, especially when required for prescribing a drug.
If government regulatory agencies increase the use of biomarkers and diagnostics in prescribing decisions, it is likely that drug and diagnostics companies will increase their collaboration. New relationships are likely to develop between partners committed to personalized medicine embracing the approach of specialized pharmaceutical firms.

Your key questions answered
* Which of the cancer diagnostic market segments are forecast to grow most rapidly through to 2016 and thus be the most commercially attractive?
* What are the key innovations in molecular diagnostics that are going to drive market growth?
* How can pharma and diagnostic companies work together to successfully develop combined drug and diagnostic products?
* Which companies are developing the most promising technologies?

Latest Reports

2012 Italy Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies
 The 2012 European Cancer Diagnostics Market: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies
2012 Global Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies
2012 World Cancer Diagnostic Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country
2012 Germany Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies
2012 UK Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies
2012 Japan Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies

World Market for Personalized Medicine Diagnostics

World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)

In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry.

The concept of ‘Personalized Medicine’, as seen by Kalorama clinical diagnostics industry analyst Shara Rosen, is currently somewhere between dream and road to reality. Fantastic promises have been made over the years in the press and reports of startup concerns. However, slowly but surely real revenues are appearing, and realistic models for future growth will be seen.

Developments that are linked in the press to ‘personalized medicine’ are many, and can at times be confusing. But there are several discovered biomarkers that are important in diagnostic markets.

Biomarkers discussed in the report include:
Cytochrome P450 and Drug Metabolism
Estrogen Receptor and Progesterone
Receptor Status for Breast Cancer
HER2 Overexpression and Herceptin and Tykerb
Epidermal Growth Factor Receptor (EGFR)
KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
BRAF Mutations and Cancer Therapy
UGT1A1 Genetic Variants
5-Flurouracil Therapy
PIK3CA Genetic Variation
KIF6 Genetic Variation
ALK Genetic Variation

This is a highly active market. A special focus of the report is the bustle of activity with collaborations between IVD and pharmaceutical companies, as well as IVD companies and CLIA labs. This report profiles scores of such companies operating in this market and estimates and forecasts markets (where there are products on the market) for personalized medicine technologies in the following categories:
Cardiac Markers, immunoassays Cardiac Risk Markers
Cardiac markers, molecular Coagulation, routine Coagulation, molecular Cancer, Tumor Markers Cancer, Molecular Cancer, Tissue-based Psychiatric Disorders Diabetes, BGM Diabetes, HbA1c Microbiology, ID/AST Infectious Diseases, Viral Load (HIV, HCV, HBV)
Infectious Diseases, other Blood Bank Molecular Transplant Tissue Typing Lab Developed Tests

Request for Sample Page                                  More about this Report…

Global Nucleic Acid Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country
2012 Global Endocrine Function Testing Market Outlook: Growth Opportunities and Strategies
2012 Global CA Tumor Markers Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country
2012 Global Immunoprotein Testing Market Outlook: Growth Opportunities and Strategies
Advances in Drug-Diagnostic Co-Development
2012 European Microbiology Testing Market: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies
Advances in Imaging Biomarkers: Innovative technologies, applications in R&D and clinical practice, and informatics and regulatory requirements
%d bloggers like this: